Skip to main content

Advertisement

Table 1 Patient demographics at diagnosis

From: Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma

Variables All patients
(n-1595)
Patients with eGFR ≥60 ml/min
(n-843)
Patients with eGFR 30–59 ml/min
(n-595)
Patients with eGFR < 30 ml/min
(n-157)
P value
Median eGFR at diagnosis (ml/min/1.73 m2) (IQR) 61 (45–79) 78 (68–92) 48 (40–54) 21 (16–25) < 0.001
Treatment arm
 Intensive (%) 907 (56.9) 536 (63.6) 290 (48.7) 81 (51.6) < 0.001
 Non-intensive (%) 688 (43.1) 307 (36.4) 305 (51.3) 76 (48.4)
Median age - years (IQR) 66 (58–73) 64 (57–70) 67 (60–75) 67 (60–73) < 0.001
Gender
 Male (%) 959 (60.1) 531 (62.9) 342 (57.4) 86 (54.7) 0.04
 Female (%) 631 (39.5) 311 (36.9) 250 (42.0) 70 (44.6)
 Unknown (%) 5 (0.3) 1 (0.1) 3 (0.5) 1 (0.6)  
Myeloma Type
 IgG (%) 977 (61.2) 534 (63.3) 371 (62.3) 72 (45.8) < 0.001
 IgA (%) 347 (21.7) 194 (23.0) 130 (21.8) 23 (14.6)
 IgM (%) 9 (0.5) 8 (0.9) 1 (0.6)
 IgD (%) 30 (1.9) 13 (1.5) 12 (2.0) 5 (3.2)
 LCO (%) 215 (13.5) 83 (9.8) 76 (12.8) 56 (35.7)
 Non-secretory myeloma (%) 17 (1.1) 11 (1.3) 6 (1.0)
FLC type
 Kappa (%) 1029 (65.2) 568 (68.3) 373 (63.3) 88 (56.1) 0.006
 Lambda (%) 549 (34.8) 264 (31.7) 216 (36.7) 69 (43.9)
Involved FLC level (mg/L)
 Median Kappa FLC (IQR) 391.20
(79.51–1106.00)
224.10
(36.96–632.20)
474.60
(115.20–1427.00)
2217.00
(668.30–5424.00)
< 0.001
 Median Lambda FLC (IQR) 503.00
(90.65–1848.00)
266.90
(57.11–942.10)
722.50
(151.40–2022.00)
3071.00
(1181.00–9079.00)